Tag Archive for: NEPC

MUC1‑C Targeting with XYA02‑8‑ADC, for Castration‑Resistant and Neuroendocrine Prostate Cancer

/in , /by

In advanced prostate cancer, castration‑resistant and neuroendocrine variants present some of the toughest clinical challenges because they often lose dependence on androgen receptor signaling and become refractory to hormone‑targeted therapies. Within this resistant landscape, MUC1‑C, the C‑terminal subunit of the mucin‑1 oncoprotein, emerges as a promising alternative target. MUC1‑C is aberrantly overexpressed and under‑glycosylated in […]

Read more

Deciparticle Everolimus: Reviving mTOR Inhibition for Neuroendocrine Prostate Cancer?

/in , /by

Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]

Read more

Phase 1/2 Trial for MK-6070 (Gocatamig): A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers

/in , , /by

MK-6070 (Gocatamig) is an engineered trispecific T-cell engager designed to target a protein called DLL3, which is predominantly found on certain aggressive neuroendocrine tumors, including prostate cancer. This molecule works by simultaneously binding to DLL3 on tumor cells, the CD3 receptor on T cells, and serum albumin, which extends the drug’s circulation time in the […]

Read more

Phase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer

/in , , , /by

NEPC

Read more

Preclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer

/in /by
Read more